●“Application of hypothesis generation using natural language processing AI to search for new influencing factors of drug-induced liver injury”
Drug-induced liver injury (DILI) is one of the leading causes of clinical trial discontinuation and post-marketing withdrawal. Elucidating the factors that influence the onset of DILI is useful for understanding its onset mechanism, but it is usually not easy to find clues to discovering such factors.
In recent years, natural language processing AI has been utilized in hypothesis generation for target or indication search, one of the most important processes in drug discovery.
In this seminar, we will focus on the relationship between DILI and genes and introduce research that examined the applicability of AI to searching for factors that influence DILI from the perspective of hypothesis generation.

● “AI drug discovery research support solution specialized for hypothesis generation”
It is currently extremely difficult for drug discovery researchers to discover target molecules with unreported association with disease. At the FRONTEO Drug Discovery AI Factory, biologists who have extensive drug discovery experience cultivated at major pharmaceutical companies and international research institutes and a deep understanding of AI utilize in-house developed natural language processing AI and use their own analysis methods.By using this, it has become possible to propose multiple highly novel target genes and their hypotheses in a short period of time.
We will introduce support for significantly improving the efficiency, acceleration, and success rate of drug discovery research through the fusion of AI and biologists.

[Date and time] October 2023, 10 (Tuesday) 31:12~00:13
Information exchange meeting (only for those participating at the real venue): 13:00-13:30 on the same day

[Format] Online (Zoom Webinars) & real venue held simultaneously
*Bento and drinks will be provided at the real venue.Please join us as a luncheon seminar.

[Venue] Nihonbashi Life Science Hub LSH-B Conference Room
(address　 Muromachi Chibagin Mitsui Building 103F, 0022-1-5 Nihonbashi Muromachi, Chuo-ku, Tokyo 5-8）
*Capacity: 20 people (first-come, first-served basis. If the capacity is exceeded, you will be placed on a waiting list for cancellations)

[Participation conditions]
We kindly ask that you refrain from applying if you are using the free address, if you are in the same industry as us, or if you do not know your affiliation.When accessing Zoom on the day, please enter your name and email address that you entered at the time of application in the entry field for Zoom participation.

FRONTEO Inc.
Executive Officer CTO Drug Discovery AI Factory Executive Officer
Director of Life Science AI Business Headquarters and Director of Behavioral Information Science Research Institute CTO
Ph.D. (Science)
Hiroyoshi Toyoshiba

Waseda University Graduate School of Science and Engineering Department of Mathematics.Since 2000, during the doctoral course in science (mathematics, obtained a doctorate in 1999), he has been in charge of statistical analysis of medical data at the Medical Information Department of Kyushu University Hospital. Since 2000, he has participated in research on carcinogenic processes by data analysis at the National Institute of Environmental Health Sciences (NIEHS). Since 2004, he has been engaged in statistical analysis of toxicity data, design of epidemiological research, and data analysis research at the National Institute for Environmental Studies. Joined Takeda Pharmaceutical Company Limited in 2006, and has served as a researcher in the field of bioinformatics, head of the Global Data Science Institute / Japan Site Bioinformatics, and a science fellow.He is also involved in gene expression data analysis and target search in clinical trial data, as well as biomarker search in immunity and cancer.
Engaged in life science AI development at FRONTEO since 2017.He develops AI algorithms specialized in the area of ​​life sciences.Utilizing the feature of vectorization of text, we have developed various AI products based on this artificial intelligence, such as research paper search, drug discovery support, dementia diagnosis support, and fall prediction.
Life Science AI CTO since 2019. In 2021, he will be appointed as an executive officer.Further promote the social implementation of AI through a mathematical approach.

FRONTEO Inc.
Neurolinguistics Research Institute Research Team
Yuna Takagi

Completed master's program at Nippon Medical and Dental University. Joined FRONTEO in April 2021 as a new graduate.He is the youngest researcher in the drug discovery unit and is familiar with KIBIT Cascade Eye and KIBIT liGALILEO technologies, which form the basis of the DD-BKM platform.Currently, he is in charge of AI analysis work as a data scientist.